In May, a historic moment in science and medicine was captured in a single photo that circulated across news outlets ...
The idea that a single-celled bacterium can defend itself against viruses in a similar way as the 1.8-trillion-cell human immune system is still “mind-blowing” for molecular biologist Joshua Modell of ...
CRISPR Therapeutics is the first company to secure an FDA approval of a gene-editing drug. That drug's underlying science, however, could be used to create treatments for any number of genetically ...
Turning genes on and off is like flipping a light switch, controlling whether genes in a cell are active. When a gene is turned on, the production of proteins or other substances is promoted; when ...
SAN DIEGO & BRISBANE, Calif.--(BUSINESS WIRE)--VedaBio, a pioneering biotechnology company transforming molecular detection, today announced a non-exclusive license agreement with Mammoth Biosciences, ...
This compares to the stock's 31.5% gain over the past four weeks. This rise in share price reflects growing investor optimism around CRISPR gene-editing technology. CRISPR Therapeutics remains the ...
CRISPR Therapeutics has developed SyNTase editing, a proprietary, next-generation, site-specific gene correction platform.
In and of itself it doesn't mean much; sickle cell disease isn't exactly a major market. The fact that the U.S. Food and Drug Administration approved any CRISPR (clustered regularly interspaced short ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback